Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels

African Health Sciences

Volumn 15, Issue 1, 2015, Pages 123-130

  Jin, Xiaoli ^a   Wu, Yulian ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biomarker; Clinical parameter; Diagnosis; Pancreatic head malignancy

Indexed keywords

BILIRUBIN; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; JAUNDICE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS TUMOR; PANCREATIC HEAD MALIGNANCY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SYMPTOMATOLOGY; WEIGHT REDUCTION; AGED; BLOOD; COMPLICATION; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ABDOMINAL PAIN; ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BILIRUBIN; BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; FEMALE; HUMANS; JAUNDICE; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84924861467     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: 10.4314/ahs.v15i1.17     Document Type: Article

References (36)

1. Benson AB, 3rd: Adjuvant therapy for pancreatic cancer: One small step forward. JAMA 2007;297:311-313.
2. Steinberg W: The clinical utility of the ca 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-355.
3. Goonetilleke KS, Siriwardena AK: Systematic review of carbohydrate antigen (ca 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-270.
4. 4. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C: Pancreatic adenocarcinoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:998-1033.
5. Nishida K, Kaneko T, Yoneda M, Nakagawa S, Ishikawa T, Yamane E, Nishioka B, Miyamoto Y, Takano H, Yoshikawa T, Kondo M: Doubling time of serum ca 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol 1999;71:140-146.
6. Duffy MJ: Ca 19-9 as a marker for gastrointesti nal cancers: A review. Ann Clin Biochem 1998;35 (Pt 3):364-370.
7. Yamaguchi T, Takahashi H, Kagawa R, Takeda R, Sakata S, Yamamoto M, Nishizaki D: Lymphoepithelial cyst of the pancreas associated with elevated ca 19-9 levels. J Hepatobiliary Pancreat Surg 2008;15:652-654.
8. DiMagno EP, Reber HA, Tempero MA: Aga technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American gastroenterological association. Gastroenterology 1999;117:1464-1484.
9. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM: Correlative study on expression of ca 19-9 and du-pan-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res 1988;48:1435-1438.
10. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V: Tumor markers in pancreatic cancer: A european group on tumor markers (egtm) status report. Ann Oncol 2010;21:441-447.
11. 11. Ahrendt SA, Pitt HA: Surgical management of pancreatic cancer. Oncology (Williston Park) 2002;16:725-734; discussion 734, 736-728, 740, 743.
12. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C: Cea, ca 19-9 and ca 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002;22:2311-2316.
13. Sandblom G, Granroth S, Rasmussen IC: Tps, ca 19-9, vegf-a, and cea as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci 2008;113:57-64.
14. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI: A new strategy for the application of ca19-9 in the differentiation of pancreaticobiliary cancer: Analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-1946.
15. Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A: The clinical utility and limitations of serum carbohydrate antigen (ca19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci 2011;56:2491-2496.
16. Zubarik R, Gordon SR, Lidofsky SD, Anderson SR, Pipas JM, Badger G, Ganguly E, Vecchio J: Screening for pancreatic cancer in a high-risk population with serum ca 19-9 and targeted eus: A feasibility study. Gastrointest Endosc 2011;74:87-95.
17. Kudo Y, Kamisawa T, Anjiki H, Takuma K, Egawa N: Incidence of and risk factors for developing pancreatic cancer in patients with chronic pancreatitis. Hepatogastroenterology 2011;58:609-611.
18. Miura F, Takada T, Amano H, Yoshida M, Furui S, Takeshita K: Diagnosis of pancreatic cancer. HPB (Oxford) 2006;8:337-342.
19. Appelqvist P, Viren M, Minkkinen J, Kajanti M, Kostiainen S, Rissanen P: Operative finding, treatment, and prognosis of carcinoma of the pancreas: An analysis of 267 cases. J Surg Oncol 1983;23:143150.
20. Watanabe I, Sasaki S, Konishi M, Nakagohri T, Inoue K, Oda T, Kinoshita T: Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 2004;28:160-165.
21. Bj Rk Werner J, Bartosch HRA, Andersson R: Cystic pancreatic lesions: Current evidence for diagnosis and treatment. Scand J Gastroenterol 2011;46:773788.
22. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW: Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-186.
23. Koeppler H, Duru M, Grundheber M, Heymanns J, Jacobs G, Pandorf A, Rendenbach B, Schimke J, Weide R: Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practices. J Support Oncol 2004;2:159-163.
24. Sommerville CA, Limongelli P, Pai M, Ahmad R, Stamp G, Habib NA, Williamson RC, Jiao LR: Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: An analysis of clinicopathological factors. J Surg Oncol 2009;100:651-656.
25. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E: Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma 2009;56:56-62.
26. Alpini G, Ueno Y, Tadlock L, Glaser SS, LeSage G, Francis H, Taffetani S, Marzioni M, Alvaro D, Patel T: Increased susceptibility of cholangiocytes to tumor necrosis factor-alpha cytotoxicity after bile duct ligation. Am J Physiol Cell Physiol 2003;285:C183-194.
27. Spirli C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, Di Virgilio F, Okolicsanyi L, Casagrande F, Strazzabosco M: Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001;121:156-169.
28. Luster MI, Simeonova PP, Gallucci R, Matheson J: Tumor necrosis factor alpha and toxicology. Crit Rev Toxicol 1999;29:491-511.
29. Sheen-Chen SM, Chen HS, Ho HT, Chen WJ, Sheen CC, Eng HL: Effect of bile acid replacement on endotoxin-induced tumor necrosis factor-alpha production in obstructive jaundice. World J Surg 2002;26:448-450.
30. Hammarstrom S: The carcinoembryonic antigen (cea) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
31. Lefor AT: What's new about cea? Curr Surg 2000;57:538-543.
32. 32. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F: Clinical utility of cea, ca 19-9, and ca 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 230301;N1 8i 1X:1G6, -B1 9 a i. XF.
33. Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P: The clinical value of serum cea, ca19-9, and ca242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005;31:164-169.
34. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E: Multivariate analysis of six serum tumor markers (cea, ca 50, ca 242, tpa, tps, tati) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res 1995;15:2731-2737.
35. Zhou J, Hu L, Yu Z, Zheng J, Yang D, Bouvet M, Hoffman RM: Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res 2010.
36. Hoffmann K, Kerner C, Wilfert W, Mueller M, Thiery J, Hauss J, Witzigmann H: Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative rt-pcr in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol 2007;13:257-263.